Table 1. Patients' Clinical and Laboratory Characteristics.
| Characteristic | Value |
|---|---|
| Number | 209 |
| Male sex, % | 69.9 |
| Age, yr | 58.3±0.6 |
| Body mass index, kg/m2 | 26.1±0.2 |
| Waist circumference, cm | 90.0±0.6 |
| Systolic blood pressure, mm Hg | 138.0±1.2 |
| Duration of diabetes, yr | 7.8±0.5 |
| C-peptide, nmol/L | 0.75±0.02 |
| HbA1c, mmol/mol | 53.0±0.6 |
| HbA1c, % | 7.0±0.1 |
| AST, IU/L | 26.2±0.8 |
| ALT, IU/L | 31.4±1.3 |
| hsCRP, mmol/L | 14.3±1.9 |
| Uric acid, µmol/L | 310.0±5.1 |
| eGFR, mL/min/1.73 m2 | 72.9±0.8 |
| UACR, mg/g | 156.3±26.5 |
| ABI | 1.2±0.1 |
| Total cholesterol, mmol/L | 4.48±0.06 |
| Triglyceride, mmol/L | 1.48±0.06 |
| HDL-C, mmol/L | 1.24±0.02 |
| LDL-C, mmol/L | 2.73±0.06 |
| Standard deviation | 2.23±0.06 |
| MAG, mmol/L/hr | 1.17±0.03 |
| Use of SU, % | 59.3 |
| Use of MET, % | 81.8 |
| Use of TZD, % | 8.1 |
| Use of DPP4i, % | 12.9 |
| Use of AGI, % | 5.7 |
| Frequency of hypoglycemia | 0.16±0.04 |
| 10-Year ASCVD risk, % | 17.1±0.8 |
Values are expressed as mean±standard error.
HbA1c, glycated hemoglobin; AST, aspartate aminotransferase; ALT, alanine aminotransferase; hsCRP, high-sensitivity C-reactive protein; eGFR, estimated glomerular filtration rate; UACR, urine albumin: creatinine ratio; ABI, ankle-brachial pressure index; HDL-C, high density lipoprotein cholesterol; LDL-C, low density lipoprotein cholesterol; MAG, mean absolute glucose change; SU, sulfonylurea; MET, metformin; TZD, thiazolidinedione; DPP4i, dipeptidyl peptidase-4 inhibitor; AGI, α-glucosidase inhibitor; ASCVD, atherosclerotic cardiovascular disease.